"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
| Descriptor ID |
D002945
|
| MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
| Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 1 | 3 | 4 |
| 1997 | 3 | 0 | 3 |
| 1998 | 3 | 0 | 3 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 5 | 5 |
| 2001 | 1 | 1 | 2 |
| 2002 | 3 | 1 | 4 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 4 | 2 | 6 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 7 | 2 | 9 |
| 2009 | 3 | 1 | 4 |
| 2010 | 1 | 5 | 6 |
| 2011 | 0 | 3 | 3 |
| 2012 | 2 | 5 | 7 |
| 2013 | 3 | 3 | 6 |
| 2014 | 4 | 1 | 5 |
| 2015 | 2 | 2 | 4 |
| 2016 | 1 | 3 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
Phase II Clinical and Translational Study of Everolimus ? Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. Oncologist. 2022 06 08; 27(6):432-e452.
-
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 04 01; 28(7):1345-1352.
-
Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury. J Lipid Res. 2022 03; 63(3):100179.
-
Cisplatin chemotherapy and renal function. Adv Cancer Res. 2021; 152:305-327.
-
Atorvastatin is associated with reduced cisplatin-induced hearing loss. J Clin Invest. 2021 01 04; 131(1).
-
Melatonin reverses nasopharyngeal carcinoma cisplatin chemoresistance by inhibiting the Wnt/?-catenin signaling pathway. Aging (Albany NY). 2020 03 23; 12(6):5423-5438.
-
Lovastatin protects against cisplatin-induced hearing loss in mice. Hear Res. 2020 04; 389:107905.
-
Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis. J Lipid Res. 2019 07; 60(7):1225-1235.
-
Clinical Prognostic Factors and Outcome in Pediatric Osteosarcoma: Effect of Delay in Local Control and Degree of Necrosis in a Multidisciplinary Setting in Lebanon. J Glob Oncol. 2019 04; 5:1-8.
-
Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy. Cancer Res. 2019 05 01; 79(9):2392-2403.